DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease.

A common polymorphism at codon 192 in the human paraoxonase (PON) 1 gene has been shown to be associated with increased risk for coronary heart disease (CHD) in Caucasian populations. However, these findings have not been reported consistently in all Caucasian and non-Caucasian populations, suggesting that this is not a functional mutation but may mark a functional mutation present in either PON1 or a nearby gene. Recently, two other PON-like genes, designated "PON2" and "PON3," have been identified, and they are linked with the known PON1 gene on chromosome 7. Identification of additional polymorphisms in the PON-gene cluster may help to locate the functional polymorphism. In this report, we describe the existence of a common polymorphism at codon 311 (Cys-->Ser; PON2*S) in the PON2 gene, as well as its association with CHD alone and in combination with the PON1 codon 192 polymorphism in Asian Indians. The frequency of the PON2*S allele was significantly higher in cases than in controls (.71 vs. .61; P=.016). The age- and sex-adjusted odds ratio (OR) was 2.5 (95% confidence interval &sqbl0;95% CI&sqbr0;=1.8-3.1; P=.0090) for the PON2*S allele carriers. Further stratification of the PON2*S association, on the basis of the presence or absence of the PON1*B allele, showed that the CHD risk associated with the PON2*S allele was confined to PON1*B-allele carriers. Likewise, the PON1*B-allele risk was present only among PON2*S carriers. Age- and sex-adjusted ORs for the PON2*S and PON1*B were 3.6 (95% CI=2.6-4.6; P=.011) and 2.9 (95% CI=2.4-3.5; P=.0002) among the PON1*B and PON2*S carriers, respectively. Our data indicate that both polymorphisms synergistically contribute to the CHD risk in this sample and that this genetic risk is independent of the conventional plasma lipid profile.

[1]  A. Nikiforova,et al.  Antioxidative activity of high density lipoproteins in vivo. , 1993, Atherosclerosis.

[2]  C. Walker,et al.  Absence of "A"-esterase activity in the serum of a patient with Tangier disease. , 1989, Clinical biochemistry.

[3]  S. Ratnam,et al.  Serum paraoxonase polymorphism in three populations of southeast Asia. , 1991, Human heredity.

[4]  C. Walker,et al.  Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. , 1986, Clinical chemistry.

[5]  C. Abbott,et al.  Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. , 1993, Atherosclerosis.

[6]  M. Jauhiainen,et al.  The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. , 1996, The Journal of clinical investigation.

[7]  M. Blatter,et al.  Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. , 1993, European journal of biochemistry.

[8]  B. La Du,et al.  Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[9]  O. Lockridge,et al.  Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. Motulsky,et al.  Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. , 1988, American journal of human genetics.

[11]  B. L. Du,et al.  Structural and functional diversity of paraoxonases , 1996, Nature Medicine.

[12]  C. Mannhalter,et al.  A rapid method for the isolation of genomic DNA from citrated whole blood. , 1991, The Biochemical journal.

[13]  D. Adler,et al.  The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.

[14]  D. Sanghera,et al.  Genetic polymorphism of paraoxonase and the risk of coronary heart disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[15]  G. Siest,et al.  An improved method for phenotyping individuals for the human serum paraoxonase arylesterase polymorphism. , 1986, Annales de biologie clinique.

[16]  G. Kitto.  Homologous enzymes and biochemical evolution. , 1969 .

[17]  M. Keifer,et al.  The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin , 1996, Nature Genetics.

[18]  G. Charpentier,et al.  Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes , 1995, The Lancet.

[19]  C. Walker,et al.  Low A-esterase activity in serum of patients with fish-eye disease. , 1987, Clinical chemistry.

[20]  D. Arveiler,et al.  The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. , 1996, Atherosclerosis.

[21]  C. Furlong,et al.  Apolipoprotein J is associated with paraoxonase in human plasma. , 1994, Biochemistry.

[22]  P. Winocour,et al.  Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. , 1991, Atherosclerosis.

[23]  S. Adkins,et al.  Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. , 1993, American journal of human genetics.

[24]  T. Diepgen,et al.  Interethnic differences in the detoxification of organophosphates: the human serum paraoxonase polymorphism. , 1986, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.

[25]  B. La Du,et al.  The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. , 1996, Genomics.

[26]  W. G. Hill,et al.  Estimation of linkage disequilibrium in randomly mating populations , 1974, Heredity.

[27]  J. Berliner,et al.  Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[28]  G. Zimmerman,et al.  The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low-density lipoprotein. , 1992, Transactions of the Association of American Physicians.

[29]  A. Marian,et al.  A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. , 1995, The Journal of clinical investigation.

[30]  P. Froguel,et al.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. , 1997, The Journal of clinical investigation.

[31]  P. Edwards,et al.  The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. , 1996, Arteriosclerosis, thrombosis, and vascular biology.